Company intelligence / Profile preview
V4CURE
Paris, Ile-de-France, Francev4cure.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
V4CURE has demonstrated potency and safety of their lead candidate V4C-232 in preclinical studies for treating volume overload conditions and rare polycystic kidney disease. They are conducting pharmacological studies and drug candidate development to prepare for Phase 1 and 2 clinical studies[1][6].
- Therapeutic areas
- GastroenterologyEndocrinologyNephrology
- Modalities
- Synthetic molecules derived from animal toxins, specifically snake venom peptides
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
CEA (French Alternative Energies and Atomic Energy Commission)
Beyond the preview
Go deeper on V4CURE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V4CURE.